OLYMPUS Investor Day 2017

Medical Business Strategy
Akihiro Taguchi
Business Management Officer,
Medical Business
Olympus Corporation
September 13, 2017

Disclaimer







2

This material contains forward-looking statements that reflect management’s current views,
plans, and expectations based on information available at the time of preparation. These
forward-looking statements are not guarantees of future performance and involve known andunknown risks, uncertainties, future business decisions, and other internal and external factorsthat may cause the Company’s actual results, performance, achievements, or financial position
to be materially different from any future results expressed or implied by these forward-looking
statements.
Additionally, this information is subject to change without notice. Accordingly, other information
should be used in addition to this material when making investment decisions.
These materials contain information on products that have not yet been approved under The
Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical
Devices (including products still under development). This information is not provided for the
purposes of advertising or offering medical advice. This information is purely meant to offer
examples of Olympus’ R&D activities. Moreover, the Company does not guarantee that products
described in these materials will actually be marketed.
Olympus Corporation assumes no responsibility for any damage resulting from the use of thismaterial.

2017/9/13

No data copy / No data transfer permitted

Medical Business Strategy

Olympus’ Vision
Olympus contributes to society by making people’s lives healthier, safer, andmore fulfilling around the world

Value to Be Provided by Medical Business

Early diagnosis

3

2017/9/13

No data copy / No data transfer permitted

Minimally invasive
therapyToday’s Agenda

1. Review of the First Year of 16CSP and Future Initiatives(Challenges and Measures)
2. Progress toward Overcoming Strategic Challenges andFuture Initiatives by Business Unit4

2017/9/13

No data copy / No data transfer permitted

Review of the First Year of 16CSP and Future Initiatives(¥ Billion)
600.0
400.0
200.0
0.0

Net Sales

Operating income

394.7

112.7

87.1

+4%*1

608.9

558.3

492.3

124.9

575.3

FY2013

FY2014FY2015FY2016FY2017(Results)(Results)(Results)(Results)(Results)

FY2017Growth rate*2(Result)

16CSP CAGR

4%

8%

Gastrointestinal
Endoscopes

4%6%

Surgical Device

4%

11%

Endotherapy
Devices7%

9%

Medical2017/9/13+1%* 115.5

140.2

Medium-Term Vision

5*Under Japanese GAAP

No data copy / No data transfer permitted

16CSP*1 Growth rates are after adjustment for foreign exchange
influences (influences in relation to FY2016).

<Net Sales> Net sales growth falls below CAGR at 4% due to mainstay
gastrointestinal endoscopes and surgical endoscopes entering the latestage of their lifecycles
 Stark difference between relatively strong performance in Europe andAsia / Oceania and struggling surgical device growth in North America<Operating income> Operating income and margin relatively unchanged YoY when theimpacts of foreign exchange influences are excluded*2 Growth rate: After adjustment for foreign exchange influences

Review of the First Year of 16CSP and Future Initiatives－GI－*Under Japanese GAAP
+4%*1(¥ Billion)

Net Sales

300.0

313.3

274.0

218.7

322.9

341.6

200.0

Medium-Term Vision

100.0
0.0

Gastrointestinal
Endoscopes

6

2017/9/13

16CSP

FY2013

FY2014FY2015FY2016FY2017(Result)(Result)(Result)(Result)(Result)*1 Growth rates are after adjustment for foreign exchange
influences (influences in relation to fiscal 2016).

FY2017Growth rate*2(Result)

16CSP CAGR

4%

6%

No data copy / No data transfer permitted

 Challenges:
 Address sluggish growth in developed countries where products werelaunched five years ago
 Measures:
 Step up scope sales and approach toward customers using competitor
products in developed countries and deploy appealing sales programs
 Secure double-digit growth in China and other parts of Asia / Oceania
 Invest in development of next-generation systems
 Expand operations related to respiratory endoscopes, ultrasoundendoscopes, and peripheral equipment (CDS, IT)*2 Growth rate: After adjustment for foreign exchange influences

Review of the First Year of 16CSP and Future Initiatives－Surgical Devices－*Under Japanese GAAP(¥ Billion)
200.0

Net Sales

159.6

127.0
100.0

0.0

179.8

+4%*1

195.0

Medium-Term Vision

182.6

16CSP

FY2013

FY2014FY2015FY2016FY2017(Result)(Result)(Result)(Result)(Result)*1 Growth rates are after adjustment for foreign exchange
influences (influences in relation to fiscal 2016).

FY2017Growthrate*2(Result)

16CSP
CAGR

4%

11%

Surgical
Device7

2017/9/13

Performance falls below targets in North America, largest market, in first year of 16CSP; issues remain for
surgical devices＜Surgical Imaging＞

Challenges: Address delays in developing de facto standard for 4K and 3D systems and prolongation of budget
execution and business negotiation periods
Measures: Provide comprehensive 4K and 3D solutions incorporating system integration services of acquired ISM andaccelerate development of de facto standard Enhance account and pipeline management
 Step up sales promotions for VISERA ELITE II＜Energy Devices＞

Challenges: Address decline in sales of products related to the PK bipolar deviceMeasures: Initiative phased recovery of PK-related sales through introduction of CTE*3 system
 Expand THUNDERBEAT operations through enhancement of already-appealing portfolioNo data copy / No data transfer permitted*2 Growth rate: After adjustment for foreign exchange influences*3 CTE: Contained Tissue Extraction System

Review of the First Year of 16CSP and Future Initiatives－ET－*Under Japanese GAAP(¥ Billion)

50.0

Net Sales

65.3

58.8

49.1

FY2013

FY2014FY2015FY2016FY2017(Result)(Result)(Result)(Result)(Result)*1 Growth rates are after adjustment for foreign exchange
influences (influences in relation to fiscal 2016).

FY2017Growth rate*2(Result)

16CSP CAGR

7%

9%Endotherapy
Devices8

2017/9/13

69.7

16CSP

Medium-Term Vision
0.0

+7%*1

72.3

No data copy / No data transfer permitted

 Current state: Growth rates in line with 16CSP targets due benefits frompast investments for strengthening sales systems andexpanding lineups（FY2015-FY2017: CAGR of 8%）
 Measures: Optimize sales organizations and systems to promote salesof single-use devices
 Continually enhance product lineups through introduction ofnew, strategic products*2 Growth rate: After adjustment for foreign exchange influences

Directives for Medical Business Strategy

Concentrate investments on 5 BUs and increase revenue and profit

GIRBU

GSBU

UGBU

ENTBU

MSBU

Gastrointestinal and Respiratory
Business Unit

General Surgery
Business Unit

Urology / Gynecology
Business Unit

Ear, Nose, and Throat
Business Unit

Medical Service
Business Unit

* The Company began disclosing performance information for the five Medical Business BUs with the announcement ofconsolidated financial results for the 1Q of FY2018 (announced on August 8, 2017).
9

2017/9/13

No data copy / No data transfer permitted

Today’s Agenda

1. Review of the First Year of 16CSP and Future Initiatives(Challenges and Measures)
2. Progress toward Overcoming Strategic Challenges andFuture Initiatives by Business Unit

10 2017/9/13

No data copy / No data transfer permitted

Gastrointestinal and Respiratory Business Unit
(GIRBU)

11 2017/9/13

No data copy / No data transfer permitted

Positioning of GIR Business within Olympus
 Core business supporting entire Company
 Target for maintaining endoscope market share and improving
profitability by increasing overall business efficiency.
 Potential for ET* business growth by leveraging the Companyʼsstrong position as a global endoscope leader.

Medical Business
Net Sales:¥570.4billion GIRBU(FY2017)

12 2017/9/13

No data copy / No data transfer permitted

310.4* Endotherapy devices

Major Products and Areas
Gastrointestinal
Endoscopes

Bronchoscopes
 Used in bronchial observation and collection oftissues and cells (biopsies, aspiration)

Endoscope Field
Endotherapy (ET)Field
13 2017/9/13＜Others＞

 Used for gastrointestinal diagnoses,
biopsies, and treatments
 Contributes to early diagnosis byhighlighting minute details of
mucous membrane structures withHD technologies, Opt-Digital
Technology (NBI*) and easy-to-use
magnified observation features

Hemostasis

Cleaning, disinfection and sterilization (CDS) Used for cleaning and high-level disinfection ofendoscopes after examinations

EMR, ESD*1

 Performed to stop bleeding after
hemorrhagic ulcer or endoscopic
treatments (EMR, ESD)*NBI: Narrow Band Imaging

No data copy / No data transfer permitted

Ultrasound endoscopes
 Used to discover lesions in deep sites that cannot
be seen on organ surfaces by using ultrasoundprobe equipped on tip of scope Entails the resection andremoval of early-stage
gastrointestinal cancer lesions
using endoscopes

ERCP*2

 Performed by inserting ET devices into bileducts via the duodenum to remove gallstones
and detect and treat bile duct functional
abnormalities*1 EMR: Endoscopic Mucosal Resection*2 ERCP: Endoscopic Retrograde Cholangio Pancreatography
ESD: Endoscopic Submucosal Dissection

Progress in Addressing Strategic Challenges (Business Strategies)

Secure strong market leader position in GI business andimprove profitability through selection and concentration
Expand business in following fields; respiratory, endoscopic
ultrasound (EUS), CDS*, and IT
Realize business growth in emerging markets
Expansion of endotherapy device business (Single-use device)

14 2017/9/13

No data copy / No data transfer permitted*CDS：Cleaning, Disinfection and Sterilization

Progress in Addressing Strategic Challenges (Business Strategies)

Secure strong market leader position in GI business andimprove profitability through selection and concentration


Secured consistent sales and maintained dominating share in developed
countries where products are in late stages of lifecycles
 Enhanced account management
 Expanded lease sales contracts (U.S., Japan)

15 2017/9/13

Achieved double-digit growth in China and other emerging countries

Addressed reprocessing issues

No data copy / No data transfer permitted

Progress in Addressing Strategic Challenges (Business Strategies)

Expand business in following fields; respiratory, endoscopic
ultrasound (EUS), CDS, and IT
Respiratory field:

 Expanded usage of EBUS-TBNA*
procedures(19% average increase in needle sales（FY2012-2016))
 Continually invested in endoscopic
treatment field

EBUS-TBNA needle（ET device）

16 2017/9/13

No data copy / No data transfer permitted

Access to peripheral
bronchial tube
(concept image)

CDS field (Cleaning, Disinfection and
Sterilization)： Achieved strong sales (average growth of
10%) for cleaning devices andconsumables in four principal regions(Japan, Europe, U.S., China)＜Growth Rates in Four Principal Regions＞

CAGR of 10%

Endoscope reprocessors
FY2012 FY2013 FY2014 FY2015 FY2016* Endobronchial Ultrasound guided Transbronchial Needle Aspiration

Progress in Addressing Strategic Challenges (Business Strategies)
Realize business growth in emerging markets＜Training center in Thailand＞

 Achieved 18% increase* in Net Sales in Asia / Oceania
 Expanded portion of total Medical Business sales
attributable to Asia / Oceania
 Established training center in Thailand to accelerate
growth in Southeast Asia

＜ Gastrointestinal Endoscopes:
Net Sales and Growth Rates* in Asia / Oceania ＞+18%

CAGR of 10%＜ Medical Business: Portion of Total Sales
Attributable to Asia / Oceania＞

18%

13%

FY2012FY201317 2017/9/13

No data copy / No data transfer permitted

FY2016FY2017* After foreign exchange adjustment

FY2017

Progress in Addressing Strategic Challenges (Business Strategies)
Expansion of endotherapy device business

Launched several strategic products in North America and other markets in line with priority strategy of
expanding product lineup

Launched products for focus areas in North America (ERCP, hemostasis, strictures), including some procured externally
Expanded portfolio and introduced differentiated and unique products

Portfolio Expansion

Differentiated and Unique Products

EndoCuff vision (Distal Hood)
QuickClipPro (Hemostasis)

CleverCut3 V（EST）

EZDilate（Endoscopic Balloon Dilator）
18 2017/9/13

No data copy / No data transfer permitted

SB knife (ESD）

StoneMasterV(Balloons with knife)

EZ Shot 3 Plus
(Ultrasound- Fine Needle)

Future Initiatives for Accomplishing 16CSP Targets
GIRBU―Net Sales: CAGR of 7%
Endoscopes (CAGR of 6%)Invest in development of next-generation endoscopy systems

Introduce product lines with features specially designed for procedure

Accelerate system replacement in developed countries / Develop an attractive sales
program
Maintain double-digit sales growth in emerging markets

 Diagnosis support using AI technologies (computer-aided diagnosis)
 3D observation endoscopes
 Motor-driven enteroscope*
 Ultrawide angle colonoscope*

Research is being conducted through cooperation with several domestic and overseas
institutions.(Image provided by Dr. Ryoichi Yamakawa of Kaetsu Hospital)

Ultrawide angle colonoscope*
19 2017/9/13

No data copy / No data transfer permitted

Motor-driven enteroscope*

3D observation endoscope*

CAD** Products are under development and are not for sale

Future Initiatives for Accomplishing 16CSP Targets
Endotherapy Devices (CAGR of 9％)Sustain strong growth through reinforcement of sales systems and expansion of strategic
lineupsStrengthen operations in North American market
 Increase number of contracts with group purchasing organizations (GPOs and IDNs)

GI Business

Develop proprietary Olympus contract programs
GI endoscopes

Reprocessors

Maintenanceservices

Endotherapy
devices

Deploy comprehensive programs combining endoscopes, reprocessors, endotherapy
devices, and maintenance services that other companies cannot imitate
20 2017/9/13

No data copy / No data transfer permitted

Urology / Gynecology Business Unit(UGBU)

21 2017/9/13

No data copy / No data transfer permitted

Positioning of UG Business within Olympus
 Core business supports ongoing business growth
UGBU  Expand business by leveraging technologies in GI and GS Potential for single-use device business growth leveraging large
endoscope market share

UGBU

61.7

22 2017/9/13

No data copy / No data transfer permitted

Medical BusinessNet sales:¥570.4billion(FY2017)

Major Products and Areas
Flexible
Ureteroscope

Flexible
Cystoscope

Urology
Gynecology
23 2017/9/13

 Flexible cystoscopes are use indiagnosis of bladder tumors
 Olympus flexible cystoscopes
have a dominating edge
realized by utilizing NBI
technologies from GI

Flexible Hysteroscope

No data copy / No data transfer permitted

 Flexible ureteroscopes areused in urinary stonetreatment Olympus flexible
ureteroscopes have adominating edge realized
by merging GI endoscope
technologies with the small
diameter scope
technologies of former
Gyrus

 Flexible hysteroscopes are used
to observe uterine fibroids andpolyps.

Stone
Treatment
Devices

Resectoscope
OES Pro.

 Stone treatment
devices are usedwith ureteroscopes
to treat stones

Therapeutic
electrodes

 Resectscope and electrodes are used to treat urology field

diseases (benign prostatic hypertrophy and bladder tumors)and gynecology field diseases (endometrial hypertrophy anduterine myoma)
 TURis* electrodes boast safety and performance of cutting
compared to monopolar devices thanks to high-frequency
energy technologies from GS.
*TURis : Transurethral Resection in salineProgress in Addressing Strategic Challenges (Business Strategies)

Urology

Secure dominant share in markets for flexible
１ endoscopes and TURis products that leverage
Olympus’s technological prowess
Strengthen urinary tract stone treatment business
２
operations to expand market share

Gynecology ３

24 2017/9/13

Efficiently increase market share by leveraging
existing products and technologies

No data copy / No data transfer permitted

Progress in Addressing Strategic Challenges (Business Strategies)
Urology

１Secure dominant share in markets for flexible endoscopes and TURis
products that leverage Olympus’s technological prowess

Boosted competitiveness of flexible scopes by soliciting
NBI technology benefits Achieved listing in bladder cancer treatment guidelines ofAmerican Urological Association
Enhanced Cystoscopy
31. In a patient with NMIBC, a clinician may consider use of NBI to increase detection and decrease
recurrence. (Conditional Recommendation; Evidence Strength: Grade C) Became applicable for reimbursement in Japan
D317 Cystoscopy
Note: Additional JPY2,000 points added for NBI highlighting when observation is conducted using
NBI(NBI highlighting points are limited to cases in which NBI is used to determine treatment policies for patients diagnosed withhaving carcinoma in situ.)

25 2017/9/13

No data copy / No data transfer permitted

Progress in Addressing Strategic Challenges (Business Strategies)
Urology

１Secure dominant share in markets for flexible endoscopes and TURis
products that leverage Olympus’s technological prowess

Maintained No. 1 position in TURis markets of Japan, the United States, and Europe
through increased sales of electrodes Introduced new TURis electrode (exhibited at EAU*1 in March 2016, launched in October) Achieved 18% growth in TURis electrode sales volumes

TURis Electrode Sales Volumes*2

New TURis electrode

Robust lineup+18%

FY201526 2017/9/13

FY2016

No data copy / No data transfer permitted*1 EAU: European Association of Urology*2 U.S., Europe, China, Japan

Progress in Addressing Strategic Challenges (Business Strategies)
Urology2

Strengthen urinary tract stone treatment business operations to expand
market share

Grew stone management business through measures advanced in various countries

Promoted spread of flexible ureterorenoscopy (FURS) using flexible ureteroscopes forremoving stones

 Achieved solid sales in the United States and exceptionally strong growth in Europe andJapan Addressed rising needs for minimally invasive therapies using FURSExpanded product portfolios
 Proposed comprehensive solutions

Lithotripsy
system27 2017/9/13

No data copy / No data transfer permitted

Stone Treatment
Devices(Enhanced product lineup)

ImagingsystemEndoscopes

MaintenanceservicesProgress in Addressing Strategic Challenges (Business Strategies)
Gynecology
3

Efficiently increase market share by leveraging existing products andtechnologies

Increased sales of hysteroscopes and related devices
 Exhibited TCRis* system at AAGL Anual Congress
 Resumed approach focusing on Gynecology resection systems (intrauterine tissue resection)using TCRis

28 2017/9/13

No data copy / No data transfer permitted*TCRis::Trans Cervical Resection in salineFuture Initiatives for Accomplishing 16CSP Targets
UGBU―Net Sales: CAGR of 8%
UrologyReinforce No. 1 position in flexible cystoscope business

Continue growing sales of TURis electrodes Expand cystoscope business by spreading use of NBI
 Promote “videonization” of cystoscopes







Address increase in number of benign prostatic hypertrophy patients
Solicit clinical evidence for TURis
Transition from laser and monopolar treatments to TURis

Strengthen marketing and development capabilities to achieve further growth in the urinary
tract stone treatment business Grow business by leveraging No. 1 position in flexible ureteroscope market
 Strengthen stone treatment device development capabilities and bolster product portfolio
 Reinforce sales systems in various countries

GynecologyContinually grow sales of hysteroscopes and Gynecology resection systems

Promote sales of TCRis electrodes in the United States

29 2017/9/13

No data copy / No data transfer permitted

Ear, Nose, and Throat Business Unit
(ENTBU)30 2017/9/13

No data copy / No data transfer permitted

Positioning of ENT Business within Olympus
 Business with high growth potential and possibility of ongoing expansion
to be realized by utilizing Olympus’ competencies
ENTBU  Target of business scope expansion using GI and GS technologies
 Set to increase earnings capacity through proactive investments instrengthening product development and sales networks

ENTBU

16.0

Medical BusinessNet sales:¥570.4billion(FY2017)31 2017/9/13

No data copy / No data transfer permitted

Major Products and Areas
Flexible laryngoscopes

Laryngology
Rhinology
Otology
32 2017/9/13

 Flexible laryngoscopes are inserted via the nasal cavity

Stroboscopy lightsourceto perform examinations in the laryngopharyngeal
region, using NBI to diagnose malignant tumors andother abnormalities

 Diagnosis vocal cord movements and detect polyps inthe larynx using strobe lights; laser probes or forceps
can be inserted via the scope channels to treat
papilloma or tumors

 Provides high-resolution endoscopic
images displaying a wide spectrumof colors via Olympus 4K system tosupport sophisticated surgeries

High-frequency ablation systems

Debriders

4K Camera heads andRigid scopes

 Used to debride diseased tissue from the sinuses

 Used to create lesions leading to

reduced volume and stiffer tissue

Ossicular Chain replacement

Vent tubes
 After making an incision in

the eardrum, vent tubes areplaced to drain effusion

No data copy / No data transfer permitted

 These implants are designed to repair
the ossicular chain in the middle ear

Business Strategies

Laryngology １
Rhinology
Overall

33 2017/9/13

Expand ENT flexible endoscope operations centeredon “videonization”

２ Acquire endoscopic sinus surgery (ESS) operations
3

Establish global sales systems

No data copy / No data transfer permitted

Progress in Addressing Strategic Challenges
Laryngology

１ Expand ENT flexible endoscope operations centered on “videonization”
Maintained impressive performance with YoY increases
in sales volumes and net sales, once again driving
growth of overall ENT business Differentiate by soliciting benefits of NBI• Conducted global training activities and advanced
differentiation by soliciting clinical benefits• Globally promoted sales of videoscopes by spreading
understanding of clinical benefits of NBI
 Promote shift from fiberscopes to videoscopes• Solicited benefits of NBI, thereby sustaining a solidtransition trend toward videoscopes in the European
Petr Lukes, M.D., Ph.D.
and North American market, which contributed toFirst Faculty of Medicine, Charles University inongoing growth in foundation businesses
Prague and University Hospital Motol

34 2017/9/13

No data copy / No data transfer permitted* Olympus ENT devices are not cleared for NBI by the FDA in the USA.

Progress in Addressing Strategic Challenges
Rhinology

2 Acquire endoscopic sinus surgery (ESS) operations

Moved ahead with growth of business focused “See & Treat” concept
revolving around 4K camera systems and DIEGO ELITE Expand ESS imaging business centered by 4K camera systems•



Won praise with superior color reproduction of 4K camera systems, andexpanded imaging business by approaching customers using competitor
products

Expand ESS treatment device (single-use device) business focused on
DIEGO ELITE•

Grew single-use device sales with differentiated high-value-added functions(high-frequency hemostasis, de-clog)•

Realized synergies with new InstaClear lens cleaning sheath
InstaClear

35 2017/9/13

No data copy / No data transfer permitted

DIEGO ELITE

Progress in Addressing Strategic Challenges
Overall

3 Establish global sales systems
Steadily advanced reinforcement of sales systems in regions ofbusiness

36 2017/9/13

Commence full-fledged development of ESS business in Japaneseand European markets• Established dedicated sales systems for Japanese market• Continued to deploy successful initiatives from the U.S. market in theJapanese and European markets

Step up development of ENT business in Asia Pacific• Made progress in constructing and strengthening dedicated sales
systems in Australia, Singapore, and South Korea• Grew sales by utilizing Company-operated sales network in China

No data copy / No data transfer permittedFuture Initiatives for Accomplishing 16CSP Targets
ENTBU―Net Sales: CAGR of 13%
Laryngology
 Reinforce operating foundations and achieve ongoing growth• Continue soliciting the clinical benefits of NBI to further reinforce operating
foundations• Achieve ongoing sales growth through launches of high-value-added products

Rhinology
 Expand ESS business• Expand lineup of new InstaClear products and DIEGO ELITE products to accelerate
ESS treatment device business• Release DIEGO ELITE in Asia following launches in Japan, the United States, andEurope37 2017/9/13

No data copy / No data transfer permitted

Medical Service Business Unit (MSBU)

38 2017/9/13

No data copy / No data transfer permitted

Positioning of MS Business within Olympus



MSBU



Recognized as a core competency of Olympus that supports overall Medical Business growth bycontinually strengthening customer contact points
Target for allocation of necessary management resources for establishing service systemfoundations in emerging countries that are projected to grow rapidly and for strengthening
systems one step ahead of competitors
Collaborative partner to manufacturing functions in streamlining and enhancing repair service
systems
Core business pursuing improved earnings capacity and steady operating profit growth
MSBU

97.3
Medical BusinessNet sales:¥570.4billion(FY2017)

39 2017/9/13

No data copy / No data transfer permitted

Major Services
General Repairs
Service Contracts
40 2017/9/13• Sales of repair services through repair bases worldwide(excluding service contracts)• Sales of repair services at facilities through field services• Single-year or multi-year contracts• Partial or complete repair cost coverage• Priority provision of loaners• Periodic inspections of contracted
equipment• Provision of failure prevention training tofacility staff

No data copy / No data transfer permitted

Progress in Addressing Strategic Challenges (Business Strategies)
MeasureDetails１

Increase service
contracts Offer breakthrough service contracts
 Realize reliable equipment operation withpreventative maintenance２

Strengthen service
operations on surgicalproducts

 Provide training to allow customers to conduct
inspections themselves
 Offer always-on-site services

Efficiently deploy repair
services and improve
productivity

 Re-establish repair service infrastructures in all
regions (reorganize existing bases, establish
new bases, etc.)
 Step up coordination efforts with
Manufacturing Group to improve productivity
and reducing repair costs

３

41 2017/9/13

No data copy / No data transfer permitted

Progress in Addressing Strategic Challenges (Business Strategies)

１

Increase service contracts
 Offer appealing service contract•

Introduced product lifecycle management guidelines for service contracts•

Commenced development of new service contracts focused on equipment uptime

 Realize reliable equipment operation with preventative maintenance•Began analyzing repair data by facility (frequency of usage cases between product failure) topropose preventative maintenance plans optimized for each facility•

Worked to improve quality of field service activities (provision of failure prevention, inspection, andtroubleshooting services, enhancement of training)

２ Strengthen service operations on surgical products
 Provide training to allow customers to conduct inspections themselves••

Formulated practical pre-use inspection methods, defined information that can beprovided in documents, and established methods of supplying these documents
Introduced surgical energy device product inspection kits Offer on-site service•
42 2017/9/13

Stepped up efforts to sell on-site service contracts in the United States

No data copy / No data transfer permitted

Surgical energy device
product inspection kit

Progress in Addressing Strategic Challenges (Business Strategies)
3

Efficiently deploy repair services and improve productivity
 Establish repair service systems in all regions• North America: Completed start-up of operations at 2nd repair base andcommenced shipments of repaired items• Europe: Finished construction of repair base in Portugal, started
reorganizing repair system

Commenced repair services in
Portugal (Europe)• Asia / Oceania: Completed relocation of major repair bases in South
Korea, Shanghai, India, etc.
• Latin America: Commenced reinforcement of repair system in Brazil【Future Directives】
Accelerate development of repair bases centered on Asia and Latin
America•

Started repair services inTennessee (North America) Strengthen efforts to further improve productivity and reduce repair costs throughcollaboration with Manufacturing Group43 2017/9/13•

Further utilize plant consulting•

Reduce repair costs

No data copy / No data transfer permitted⇒ Conduct plant consulting at repair bases andcultivate plant consultants⇒ Create repair units at repair bases

Future Initiatives for Accomplishing 16CSP Targets
MSBU―Net Sales: CAGR of 5%
Increase service contracts and improve profitability
 Increase service contract
 Develop appealing service contracts focused on equipment uptime
 Realize reliable equipment operation with preventative maintenance Improve profitability
 Achieve efficient operation through consolidation of repair bases
 Increase contract profitability by lowering incidences of repairs through preventative
maintenance Efficiently utilize loaners and repair parts
 Coordinate with Manufacturing Group to improve repair work efficiency
44 2017/9/13

No data copy / No data transfer permitted